由厦门大学国家传染病诊断试剂与疫苗工程技术研究中心研制、厦门万泰沧海生物技术有限公司实现产业转化的世界首支戊型肝炎疫苗益可宁，27日在厦门正式上市。

By the xiamen university national infectious disease diagnosis reagent and vaccine engineering technology research center development/Xiamen wantai the sea and the biological technology co., LTD., to realize the transformation of the first industry of the world a hepatitis a vaccine profit can be better,27 officially listed in xiamen.

　　戌型肝炎是目前在全世界蔓延的急性流行病毒性肝炎，其症状与甲型肝炎相似，但病死率更高，尤其对孕妇、老年人和慢性肝病患者危害更大。世界卫生组织2012年7月提供的数据显示，全世界每年约有2000万人感染戌型肝炎。但此前全世界并没有针对戊型肝炎感染的有效治疗手段。

Xu-gou (hepatitis b is at present in the world spread of acute popular viral hepatitis,Its symptoms and hepatitis a similar,But higher mortality,Especially for pregnant women/The elderly patients with chronic liver disease and more harmful.The world health organization in July 2012 to provide the data display,The world each year about 20 million people have been infected with hepatitis xu-gou.But after the world and not for hepatitis e infection of the effective treatment method.

　　益可宁上市前进行了为期2年、有11.3万人参与的大规模第三期临床试验。结果表明，疫苗对接种志愿者起到了理想的保护作用。中国科学家对戊型肝炎疫苗的成功研制被国际医药领域科学界和产业界誉为“全世界戊型肝炎防控领域的一个重大突破”。

Profit can be better before the listing for 2 years/There are 113000 people participate in the third stage of large-scale clinical trials.The results show that,Vaccine inoculation volunteers to play a ideal of protection.Chinese scientists hepatitis a vaccine for the successful design of the medical field by the international scientific community and industry known as"The world hepatitis prevention and control areas of a major breakthrough".

　　中国肝炎防治基金会为益可宁成功上市，27日在厦门举办“戊肝流行病学与危害研讨会暨全球首创戊肝疫苗宣传推广会”。200多位来自卫生部、科技部、中国疾病预防控制中心和全国各地的专家、学者，就戊型肝炎流行现状、中国戊型肝炎流行病学及控制策略等发表专题演讲。

China hepatitis prevention and treatment foundation for the successful listing can be better,27 held in xiamen"Hepatitis e epidemiology and hazard seminar global initiative amyl liver vaccine task-calling promotional meetings".More than 200 from the ministry of health/Ministry of science and technology/China's center for disease control all over the country and the experts/scholars,Is hepatitis popular status/China hepatitis epidemiology and control strategies deliver a keynote speech.

　　益可宁为世界创新疫苗研制开辟了一条新途径。厦门大学国家传染病诊断试剂与疫苗工程技术研究中心采用大肠杆菌作为表达系统，独创与酵母、昆虫细胞、哺乳动物细胞并行的第四基因工程疫苗研发路径，历经14年探索，投入近5亿元，为中国生物制药打破国际垄断搭建起独立自主的原始创新平台。

The world can be better for innovation vaccine development has developed a new way.Xiamen university national infectious disease diagnosis reagent and vaccine engineering technology research center using escherichia coli as expression system,Original creation and yeast/Insect cell/Mammalian cells parallel fourth genetic engineering vaccine development path,After 14 years exploration,Investment of nearly 500 million yuan,For Chinese biopharmaceutical break international monopoly set up independent original innovation platform.

　　厦门万泰沧海生物技术有限公司总经理高永忠表示，公司将尽快把疫苗应用于育龄妇女、学生、老年人等高危人群的预防，同时积极与世界卫生组织及其他国际公益组织合作，争取使该疫苗能尽快造福于其他戊肝高流行国家和地区的民众。(记者 余瑛瑞)

Xiamen wantai the sea and the biological technology co., LTD., general manager GaoYongZhong said,The company will as soon as possible the vaccine used in women of child-bearing age/students/Old high-risk groups of prevention,At the same time, positive and the world health organization and other international public welfare organizations,To make the vaccine can as soon as possible in the service of other hepatitis e high pop countries and regions of people.(Reporter YuYingRui)